Cartesian Therapeutics (RNAC) Operating Income (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Operating Income of -$26.5 million for Q1 2026, down 21.06% year-over-year from -$33.6 million in Q1 2025, and up 66.3% quarter-over-quarter from -$78.6 million in Q4 2025.
Cartesian Therapeutics (RNAC) Operating Income (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Operating Income data on file, last reported at -$26.5 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$26.5 million, down 21.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$148.0 million (down 182.27% YoY), and the FY2025 annual result was -$143.4 million, down 226.69% from the prior year.
- Operating Income climbed to -$26.5 million in Q1 2026 per RNAC's latest filing, from -$78.6 million in the prior quarter.
- Over five years, Operating Income peaked at $13.9 million in Q2 2022 and troughed at -$78.6 million in Q4 2025.
- A 5-year average of -$16.8 million and a median of -$18.4 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income surged 2966.37% in 2022, then plunged 717.07% in 2023.
- A 5-year view of Operating Income shows it stood at -$8.5 million in 2022, then plunged by 327.64% to -$36.3 million in 2023, then advanced by 26.43% to -$26.7 million in 2024, then tumbled by 194.19% to -$78.6 million in 2025, then jumped by 66.3% to -$26.5 million in 2026.
- Business Quant data shows RNAC's Operating Income at -$26.5 million in Q1 2026, -$78.6 million in Q4 2025, and -$21.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -26.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.50 Mn |
| Dec 31, 2025 | -78.64 Mn |
| Sep 30, 2025 | -21.07 Mn |
| Jun 30, 2025 | -21.81 Mn |
| Mar 31, 2025 | -21.89 Mn |
| Dec 31, 2024 | -26.73 Mn |
| Sep 30, 2024 | -17.58 Mn |
| Jun 30, 2024 | 13.76 Mn |
| Mar 31, 2024 | -13.35 Mn |
| Dec 31, 2023 | -36.33 Mn |
| Sep 30, 2023 | -13.07 Mn |
| Jun 30, 2023 | -18.64 Mn |
| Mar 31, 2023 | -18.38 Mn |
| Dec 31, 2022 | -8.50 Mn |
| Sep 30, 2022 | -1.60 Mn |
| Jun 30, 2022 | 13.86 Mn |
| Mar 31, 2022 | 10.77 Mn |
| Dec 31, 2021 | 4.08 Mn |
| Sep 30, 2021 | -1.97 Mn |
| Jun 30, 2021 | 452,000.00 |